Hishan Tharmaseelan

6PUBLICATIONS
23CO-AUTHORS
Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 17, 2026
Prognostic impact of presentation phenotypes in early-stage favorable Hodgkin lymphoma.

|Jul 17, 2025
Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.

Justin Ferdinandus, Helen Kaul, Alexander Fosså

|Jul 11, 2025
Sequential BCMA CAR T-cell therapy in refractory multiple myeloma.

Tim Richardson, Udo Holtick, Jan-Hendrik Frenking

|Mar 30, 2025
Correction: Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials.

P J Bröckelmann, H Müller, M Fuchs

|Mar 25, 2025
Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials.

P J Bröckelmann, H Müller, M Fuchs

|Nov 15, 2024
Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma.

Tim Richardson, Hishan Tharmaseelan, Lukas Frenzel

Pageof 1

Frequent Collaborators

4 joint publications

Dennis A Eichenauer

3 joint publications

Paul J Bröckelmann

3 joint publications

Justin Ferdinandus

3 joint publications

Carsten Kobe